WuXi XDC Sets IPO Price at Top of End of Range
By P.R. Venkat
A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong.
The company said Wuxi XDC Cayman will raise 3.68 billion Hong Kong dollars, the equivalent of $470.9 million, after the final IPO price was set at HK$20.60 a share.
The company had marketed the shares at a price range of HK$19.90 to HK$20.60/share.
People familiar with the deal had said earlier that Wuxi XDC closed its order book early due to strong demand.
Shares of the company, which does research, development and manufacturing with a focus on antibody-drug conjugate, a type of medicine for cancer treatment, will start trading on the Hong Kong exchange Nov. 17.
The IPO secured commitments from some global investors, including Invesco, Qatar's sovereign wealth fund, and HongShan, the investment firm formerly known as Sequoia Capital China, according to Wuxi XDC's listing document.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
November 15, 2023 18:22 ET (23:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks